|
1
|
Murawa P, Murawa D, Adamczyk B and Polom
K: Breast cancer: Actual methods of treatment and future trends.
Rep Pract Oncol Radiother. 19:165–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Serpico D, Molino L and Di Cosimo S:
microRNAs in breast cancer development and treatment. Cancer Treat
Rev. 40:595–604. 2014. View Article : Google Scholar
|
|
3
|
Brower J, Clark PA, Lyon W and Kuo JS:
MicroRNAs in cancer: Glioblastoma and glioblastoma cancer stem
cells. Neurochem Int. 77:68–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishiguro H, Kimura M and Takeyama H: Role
of microRNAs in gastric cancer. World J Gastroenterol.
20:5694–5699. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bouyssou JM, Manier S, Huynh D, Issa S,
Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer
metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
|
|
6
|
Kotaja N: MicroRNAs and spermatogenesis.
Fertil Steril. 101:1552–1562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shah NR and Chen H: MicroRNAs in
pathogenesis of breast cancer: Implications in diagnosis and
treatment. World J Clin Oncol. 5:48–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu J, Zheng Z, Wang J, et al: Different
miRNA expression profiles between human breast cancer tumors and
serum. Front Genet. 5:1492014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu Z, Huang X, Zou Q and Guo Y: The
inhibitory role of Mir-29 in growth of breast cancer cells. J Exp
Clin Cancer Res. 32:982013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishikawa R, Goto Y, Kojima S, et al:
Tumor-suppressive microRNA-29 s inhibit cancer cell migration and
invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014.PubMed/NCBI
|
|
11
|
Yang Y, Gu X, Zhou M, Xiang J and Chen Z:
Serum microRNAs: A new diagnostic method for colorectal cancer.
Biomed Rep. 1:495–498. 2013.
|
|
12
|
Lu L, Xue X, Lan J, et al: MicroRNA-29a
upregulates MMP2 in oral squamous cell carcinoma to promote cancer
invasion and anti-apoptosis. Biomed Pharmacother. 68:13–19. 2014.
View Article : Google Scholar
|
|
13
|
Chaturvedi S and Robinson LA: Slit2-Robo
signaling in inflammation and kidney injury. Pediatr Nephrol.
30:561–566. 2015. View Article : Google Scholar
|
|
14
|
Yang YH, Manning Fox JE, Zhang KL,
MacDonald PE and Johnson JD: Intraislet SLIT-ROBO signaling is
required for beta-cell survival and potentiates insulin secretion.
Proc Natl Acad Sci USA. 110:16480–16485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuen DA and Robinson LA: Slit2-Robo
signaling: a novel regulator of vascular injury. Curr Opin Nephrol
Hypertens. 22:445–451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cornide-Petronio ME and Barreiro-Iglesias
A: Role of Slit and Robo proteins in the development of
dopaminergic neurons. Dev Neurosci. 35:285–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dickinson RE and Duncan WC: The SLIT-ROBO
pathway: a regulator of cell function with implications for the
reproductive system. Reproduction. 139:697–704. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ballard MS and Hinck L: A roundabout way
to cancer. Adv Cancer Res. 114:187–235. 2012.PubMed/NCBI
|
|
19
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong L, Zhu K, Jin N, et al: A systematic
analysis of miRNA-mRNA paired variations reveals widespread miRNA
misregulation in breast cancer. Biomed Res Int. 2014:2912802014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu PN, Yan MD, Lai HC, et al:
Downregulation of miR-29 contributes to cisplatin resistance of
ovarian cancer cells. Int J Cancer. 134:542–551. 2014. View Article : Google Scholar
|
|
22
|
Zhao D, Jiang X, Yao C, et al: Heat shock
protein 47 regulated by miR-29a to enhance glioma tumor growth and
invasion. J Neurooncol. 118:39–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Q, Wang C, Lu Z, Guo L and Ge Q:
Analysis of serum genome-wide microRNAs for breast cancer
detection. Clin Chim Acta. 413:1058–1065. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu YQ, Gong G, Xu ZL, et al: miRNA
profiling reveals a potential role of milk stasis in breast
carcinogenesis. Int J Mol Med. 33:1243–1249. 2014.PubMed/NCBI
|
|
25
|
Dontula R, Dinasarapu A, Chetty C, et al:
MicroRNA 203 modulates glioma cell migration via Robo1/ERK/MMP-9
signaling. Genes Cancer. 4:285–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alajez NM, Lenarduzzi M, Ito E, et al:
MiR-218 suppresses nasopharyngeal cancer progression through
downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res.
71:2381–2391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Khusial PR, Vadla B, Krishnan H, et al:
Src activates Abl to augment Robo1 expression in order to promote
tumor cell migration. Oncotarget. 1:198–209. 2010.
|
|
28
|
Yang L, Li Q, Wang Q, Jiang Z and Zhang L:
Silencing of miRNA-218 promotes migration and invasion of breast
cancer via Slit2-Robo1 pathway. Biomed Pharmacother. 66:535–540.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tie J, Pan Y, Zhao L, et al: MiR-218
inhibits invasion and metastasis of gastric cancer by targeting the
Robo1 receptor. PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
